Evaluation of selenium status and effectiveness of selenolin in the treatment of selenium-dependent hepatopathies

• Main Authors: Grin Vladimir A., Rogaleva Eugenia V., Semenenko Marina P., Semenenko Ksenia A., Kuzminova Elena V.
• Format: Article
• Language: English
• Published: EDP Sciences 2021-01-01
• Series: E3S Web of Conferences
• Online Access: https://www.e3s-conferences.org/articles/e3sconf/pdf/2021/38/e3sconf_iteea2021_02004.pdf

The article is devoted to the study of the assessment of selenium status in the pathogenesis of liver diseases and the effectiveness of the use of a selenium-containing drug. In the course of studies in animals with clinical signs and high rates of hepatopathies markers – transaminases, in 100% of cases a low level of selenium was revealed – 0.026 ±0.01 μg / ml, because of the increased consumption of this microelement on the background of increased free radical oxidation processes in the liver tissue. It was found that intramuscular administration of the drug selenolin at a dose of 20 mg / 100 kg four times with an interval of 15 days significantly improved the clinical status of the experimental animals; the effectiveness of therapy was 93.3%. Parenteral administration of selenolin favorably corrected the processes of lipid peroxidation and contributed to a significant (p <0.01) decrease in the level of liver indicator enzymes in comparison with the control by 34.5% (aspartate aminotransferase) and by 45.8% (alanine aminotransferase), and also contributed to an increase in the level of selenium to the level of the physiological norm (0.068 ± 0.03 μg / ml).